Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 2, 2008, Pages 430-437

  Ooi, Esther M M ^a   Watts, Gerald F ^a   Nestel, Paul J ^b   Sviridov, Dmitri ^b   Hoang, Anh ^b   Barrett, P Hugh R ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CATABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; HUMAN; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 39049106149     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-0854     Document Type: Article

References (44)

1. Barter PJ, Rye KA 2006 Relationship between the concentration and antiatherogenic activity of high-density lipoproteins. Curr Opin Lipidol 17:399-403
2. Chan DC, Barrett PH, Watts GF 2006 Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders. Curr Opin Lipidol 17:28-36
3. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L 2004 Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTER-HEART study): case-control study. Lancet 364:937-952
4. Wallenfeldt K, Bokemark L, Wikstrand J, Hulthe J, Fagerberg B 2004 Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke 35:2248-2252
5. Cheung MC, Albers JJ 1982 Distribution of high density lipoprotein particles with different apoprotein composition: particles with A-I and A-II and particles with A-I but no A-II. J Lipid Res 23:747-753
6. Huang Y, von Eckardstein A, Wu S, Assmann G 1995 Cholesterol efflux, cholesterol esterification, and cholesteryl ester transfer by LpA-I and LpA-I/A-II in native plasma. Arterioscler Thromb Vasc Biol 15:1412-1418
7. Schultz JR, Verstuyft JG, Gong EL, Nichols AV, Rubin EM 1993 Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature 365:762-764
8. Barbaras R, Puchois P, Fruchart JC, Ailhaud G 1987 Cholesterol efflux from cultured adipose cells is mediated by LpAI particles but not by LpAI:AII particles. Biochem Biophys Res Commun 142:63-69
9. Montali A, Vega GL, Grundy SM 1994 Concentrations of apolipoprotein A-I-containing particles in patients with hypoalphalipoproteinemia. Arterioscler Thromb 14:511-517
10. Puchois P, Kandoussi A, Fievet P, Fourrier JL, Bertrand M, Koren E, Fruchart JC 1987 Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis 68:35-40
11. Grundy SM 1998 Statin trials and goals of cholesterol-lowering therapy. Circulation 97:1436-1439
12. Schaefer EJ, Asztalos BF 2006 The effects of statins on high-density lipoproteins. Curr Atheroscler Rep 8:41-49
13. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, Najib-Fruchart J, Glineur C, Staels B 2001 Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I. J Clin Invest 107:1423-1432
14. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW 2003 Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 92:152-160
15. Stalenhoef AF, Ballantyne CM, Sarti C, Murin J, Tonstad S, Rose H, Wilpshaar W 2005 A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J 26:2664-2672
16. Ooi EMM, Barrett PHR, Chan DC, Nestel PJ, Watts GF 2007 Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome. Atherosclerosis 10.1016/j.atherosclerosis.2007.03.004
17. 2001 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497
18. Watts GF, Barrett PH, Ji Juying, Serone AP, Chan DC, Croft K.D., Loehrer F, Johnson AG 2003 Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 52:803-811
19. Rader DJ, Castro G, Zech LA, Fruchart JC, Brewer Jr HB 1991 In vivo metabolism of apolipoprotein A-I on high density lipoprotein particles LpA-I and LpA-I, A-II. J Lipid Res 32:1849-1859
20. Syvanne M, Kahri J, Virtanen KS, Taskinen MR 1995 HDLs containing apolipoproteins A-I and A-II (LpA-I:A-II) as markers of coronary artery disease in men with non-insulin-dependent diabetes mellitus. Circulation 92:364-370
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
22. Olchawa B, Kingwell BA, Hoang A, Schneider L, Miyazaki O, Nestel P, Sviridov D 2004 Physical fitness and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 24:1087-1091
23. Ji J, Watts GF, Johnson AG, Chan DC, Ooi EM, Rye KA, Serone AP, Barrett PH 2006 High-density lipoprotein (HDL) transport in the metabolic syndrome: application of a new model for HDL particle kinetics. J Clin Endocrinol Metab 91:973-979
24. Zech LA, Schaefer EJ, Bronzert TJ, Aamodt RL, Brewer Jr HB 1983 Metabolism of human apolipoproteins A-I and A-II: compartmental models. J Lipid Res 24:60-71
25. Bilz S, Wagner S, Schmitz M, Bedynek A, Keller U, Demant T 2004 Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. J Lipid Res 45:174-185
26. Mauger JF, Couture P, Paradis ME, Lamarche B 2005 Comparison of the impact of atorvastatin and simvastatin on apoA-I kinetics in men. Atherosclerosis 178:157-163
27. Chan DC, Watts GF, Nguyen MN, Barrett PH 2006 Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity. Am J Clin Nutr 84:37-43
28. Brinton EA, Eisenberg S, Breslow JL 1994 Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb 14:707-720
29. Frenais R, Nazih H, Ouguerram K, Maugeais C, Zair Y, Bard JM, Charbonnel B, Magot T, Krempf M 2001 In vivo evidence for the role of lipoprotein lipase activity in the regulation of apolipoprotein AI metabolism: a kinetic study in control subjects and patients with type II diabetes mellitus. J Clin Endocrinol Metab 86:1962-1967
30. Pietzsch J, Julius U, Nitzsche S, Hanefeld M 1998 In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Diabetes 47:1928-1934
31. Rashid S, Watanabe T, Sakaue T, Lewis GF 2003 Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 36:421-429
32. Asztalos BF, Le Maulf F, Dallal GE, Stein E, Jones PH, Horvath KV, McTaggart F, Schaefer EJ 2007 Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins. Am J Cardiol 99:681-685
33. Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ 2000 Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 20:189-197
34. Le NA, Innis-Whitehouse W, Li X, Bakker-Arkema R, Black D, Brown WV 2000 Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin. Metabolism 49:167-177
35. Caslake MJ, Stewart G, Day SP, Daly E, McTaggart F, Chapman MJ, Durrington P, Laggner P, Mackness M, Pears J, Packard CJ 2003 Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. Atherosclerosis 171:245-253
36. Newnham HH, Barter PJ 1992 Changes in particle size of high density lipoproteins during incubation with very low density lipoproteins, cholesteryl ester transfer protein and lipoprotein lipase. Biochim Biophys Acta 1125:297-304
37. Rashid S, Uffelman KD, Lewis GF 2002 The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. J Diabetes Complications 16:24-28
38. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM 2006 Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295:1556-1565
39. Nicholls SJ, Schoenhagen P, Tuzcu EM, Hu T, Sipahi I, Grasso AW, Wolski K, Desai MY, Hazen SL, Nissen SE, Crowe T, Kapadia SR 2007 Statin-mediated increases in HDL cholesterol promote regression of coronary atherosclerosis: insights from intravascular ultrasound. J Am Coll Cardiol 49(Suppl A):1014-1120
40. Brousseau ME, Diffenderfer MR, Millar JS, Nartsupha C, Asztalos BF, Welty FK, Wolfe ML, Rudling M, Bjorkhem I, Angelin B, Mancuso JP, Digenio AG, Rader DJ, Schaefer EJ 2005 Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 25:1057-1064
41. Barrett PH, Chan DC, Watts GF 2006 Thematic review series: patient-oriented research. Design and analysis of lipoprotein tracer kinetics studies in humans. J Lipid Res 47:1607-1619
42. Tilly-Kiesi M, Lichtenstein AH, Joven J, Vilella E, Cheung MC, Carrasco WV, Ordovas JM, Dolnikowski G, Schaefer EJ 1997 Impact of gender on the metabolism of apolipoprotein A-I in HDL subclasses LpAI and LpAI:AII in older subjects. Arterioscler Thromb Vasc Biol 17:3513-3518
43. Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD 2006 Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 368:919-928
44. Hixson JE, Vernier DT 1990 Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31:545-548